Literature DB >> 8350313

Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide.

H Groen1, H Bootsma, D S Postma, C G Kallenberg.   

Abstract

Pulmonary hypertension was diagnosed in a patient with SLE after her 5th delivery. Time of onset and absence of thromboembolism and severe interstitial lung disease suggested primary pulmonary hypertension. Administration of vasodilators did not decrease pulmonary artery pressure which amounted to 82/30 mm Hg. Cyclophosphamide infusions, 0.5 g/m2 monthly for 6 months followed by once/3 months, in combination with 7.5 mg prednisolone daily resulted in decrease of pulmonary artery pressure to 66/34 mm Hg after 6 months of treatment persisting for 30 months. Intermittent infusions of cyclophosphamide with low dose prednisolone may be effective in primary pulmonary hypertension in SLE, suggesting an immune mediated pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8350313

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

Review 1.  Treatment of pulmonary hypertension secondary to connective tissue diseases.

Authors:  O Sanchez; M Humbert; O Sitbon; G Simonneau
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

2.  Improvement of severe pulmonary hypertension in a patient with SLE.

Authors:  M Karmochkine; B Wechsler; P Godeau; F Brenot; J L Jagot; G Simonneau
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

3.  Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease.

Authors:  Shikha Mittoo; Thomas Jacob; Andrea Craig; Zoheir Bshouty
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

4.  Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension.

Authors:  Son-Mi Chung; Chang-Keun Lee; Eun Young Lee; Bin Yoo; Sang-Do Lee; Hee-Bom Moon
Journal:  Clin Rheumatol       Date:  2006-02-22       Impact factor: 2.980

Review 5.  Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.

Authors:  Rohit Moudgil; Edward T H Yeh
Journal:  Can J Cardiol       Date:  2016-02-02       Impact factor: 5.223

6.  Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide.

Authors:  Eri Sugawara; Masaru Kato; Ryo Hisada; Kenji Oku; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi
Journal:  Intern Med       Date:  2017-02-15       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.